Fimasartan

Possibly Marketed Outside US

Details

Stereochemistry	ACHIRAL
Molecular Formula	C27H31N7OS
Molecular Weight	501.646
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

SMILES

CCCCC1=NC(C)=C(CC(=S)N(C)C)C(=O)N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NN=NN4

InChI

InChIKey=AMEROGPZOLAFBN-UHFFFAOYSA-N

InChI=1S/C27H31N7OS/c1-5-6-11-24-28-18(2)23(16-25(36)33(3)4)27(35)34(24)17-19-12-14-20(15-13-19)21-9-7-8-10-22(21)26-29-31-32-30-26/h7-10,12-15H,5-6,11,16-17H2,1-4H3,(H,29,30,31,32)

HIDE SMILES / InChI

Molecular Formula	C27H31N7OS
Molecular Weight	501.646
Charge	0
Count	MOL RATIO 1 MOL RATIO (average)

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description

Fimasartan is a angiotensin II receptor antagonist which was developed in Korea for the treatment of hypertension. The drug is available in different forms: Kanarb, Dukarb (in combination with Amlodipine), Tuvero (in combination with Rosuvastatin). Fimasartan was tested to be effective in Mexican and Russian population and now is being tested in the USA.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Angiotensin II receptor 9	Antagonist 2,849		0.13 nM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Essential hypertension 17	Primary		Approved 8,583	KANARB

C_max

Value	Dose	Analyte	Population
11.6 ng/mL	20 mg single, oral	FIMASARTAN plasma	Homo sapiens
66.2 ng/mL	60 mg single, oral	FIMASARTAN plasma	Homo sapiens
136 ng/mL	120 mg single, oral	FIMASARTAN plasma	Homo sapiens
227 ng/mL	240 mg single, oral	FIMASARTAN plasma	Homo sapiens
601 ng/mL	480 mg single, oral	FIMASARTAN plasma	Homo sapiens
123 ng/mL	120 mg 1 times / day multiple, oral	FIMASARTAN plasma	Homo sapiens
224 ng/mL	120 mg 1 times / day multiple, oral	FIMASARTAN plasma	Homo sapiens
309 ng/mL	360 mg 1 times / day multiple, oral	FIMASARTAN plasma	Homo sapiens
403 ng/mL	360 mg 1 times / day multiple, oral	FIMASARTAN plasma	Homo sapiens
227 ng/mL	240 mg single, oral	FIMASARTAN plasma	Homo sapiens
183 ng/mL	240 mg single, oral	FIMASARTAN plasma	Homo sapiens
289.3 ng/mL	120 mg single, oral	FIMASARTAN plasma	Homo sapiens
422 ng/mL	120 mg single, oral	FIMASARTAN plasma	Homo sapiens
1864.4 ng/mL	120 mg single, oral	FIMASARTAN plasma	Homo sapiens
281.9 μg/mL	120 mg single, oral	FIMASARTAN plasma	Homo sapiens
457.7 μg/mL	120 mg single, oral	FIMASARTAN plasma	Homo sapiens

AUC

Value	Dose	Analyte	Population
98.8 ng × h/mL	20 mg single, oral	FIMASARTAN plasma	Homo sapiens
413 ng × h/mL	60 mg single, oral	FIMASARTAN plasma	Homo sapiens
783 ng × h/mL	120 mg single, oral	FIMASARTAN plasma	Homo sapiens
1116 ng × h/mL	240 mg single, oral	FIMASARTAN plasma	Homo sapiens
2448 ng × h/mL	480 mg single, oral	FIMASARTAN plasma	Homo sapiens
636 ng × h/mL	120 mg 1 times / day multiple, oral	FIMASARTAN plasma	Homo sapiens
801 ng × h/mL	120 mg 1 times / day multiple, oral	FIMASARTAN plasma	Homo sapiens
1157 ng × h/mL	360 mg 1 times / day multiple, oral	FIMASARTAN plasma	Homo sapiens
1441 ng × h/mL	360 mg 1 times / day multiple, oral	FIMASARTAN plasma	Homo sapiens
1116 ng × h/mL	240 mg single, oral	FIMASARTAN plasma	Homo sapiens
1033 ng × h/mL	240 mg single, oral	FIMASARTAN plasma	Homo sapiens
932 ng × h/mL	120 mg single, oral	FIMASARTAN plasma	Homo sapiens
1509.7 ng × h/mL	120 mg single, oral	FIMASARTAN plasma	Homo sapiens
4768.1 ng × h/mL	120 mg single, oral	FIMASARTAN plasma	Homo sapiens
913.6 μg × h/mL	120 mg single, oral	FIMASARTAN plasma	Homo sapiens
1580.8 μg × h/mL	120 mg single, oral	FIMASARTAN plasma	Homo sapiens

T_1/2

Value	Dose	Analyte	Population
5.53 h	20 mg single, oral	FIMASARTAN plasma	Homo sapiens
5.37 h	60 mg single, oral	FIMASARTAN plasma	Homo sapiens
9.33 h	120 mg single, oral	FIMASARTAN plasma	Homo sapiens
10.1 h	240 mg single, oral	FIMASARTAN plasma	Homo sapiens
16.2 h	480 mg single, oral	FIMASARTAN plasma	Homo sapiens
4.73 h	120 mg 1 times / day multiple, oral	FIMASARTAN plasma	Homo sapiens
14 h	120 mg 1 times / day multiple, oral	FIMASARTAN plasma	Homo sapiens
5.71 h	360 mg 1 times / day multiple, oral	FIMASARTAN plasma	Homo sapiens
17.9 h	360 mg 1 times / day multiple, oral	FIMASARTAN plasma	Homo sapiens
10.1 h	240 mg single, oral	FIMASARTAN plasma	Homo sapiens
13.1 h	240 mg single, oral	FIMASARTAN plasma	Homo sapiens
7.4 h	120 mg single, oral	FIMASARTAN plasma	Homo sapiens
8.2 h	120 mg single, oral	FIMASARTAN plasma	Homo sapiens
8.5 h	120 mg single, oral	FIMASARTAN plasma	Homo sapiens
9.8 h	120 mg single, oral	FIMASARTAN plasma	Homo sapiens
11.35 h	120 mg single, oral	FIMASARTAN plasma	Homo sapiens

F_unbound

Value	Dose	Co-administered	Analyte	Population
5%			FIMASARTAN plasma	Homo sapiens

Doses

Show entries

Dose	Population	Adverse events
480 mg single, oral Highest studied dose	healthy, ADULT
360 mg 1 times / day multiple, oral Studied dose	healthy, ADULT	Other AEs: Blood pressure decreased...

Showing 1 to 2 of 2 entries

Previous1Next

AEs

Show entries

AE	Significance	Dose	Population
Blood pressure decreased		360 mg 1 times / day multiple, oral Studied dose	healthy, ADULT

Showing 1 to 1 of 1 entries

Previous1Next

PubMed

Show entries

Title	Date	PubMed
Influence of Fimasartan (a Novel AT(1) Receptor Blocker) on Catecholamine Release in the Adrenal Medulla of Spontaneously Hypertensive Rats.	2013 Feb	23441003

Showing 1 to 1 of 1 entries

Previous1Next

Patents

Sample Use Guides

In Vivo Use Guide

Fimasartan is taken as a single oral dose of 60-mg tablet or a single 30-mg intravenous (IV) infusion.

Route of Administration: Other

In Vitro Use Guide

Rabbit thoracic aorta cells were incubated with different concentrations of fimasartan ((0.1, 1, 10 nM). At those concentrations fimasartan caused nonparallel rightward shifts in the concentration–contractile response curve to Ang II with a significant reduction in the maximal contractile response to 96.6, 47 and 18%, respectively.